[{"id":"faa6b9ee-e5b7-4857-a716-679458f2b01b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01376505","created_at":"2021-01-18T05:38:31.071Z","updated_at":"2025-02-25T13:59:55.799Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Treating Patients With Metastatic Solid Tumors","source_id_and_acronym":"NCT01376505","lead_sponsor":"Robert Wesolowski","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 expression • EGFR expression","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 expression • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • B-Vaxx"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 06/21/2011","start_date":" 06/21/2011","primary_txt":" Primary completion: 11/28/2022","primary_completion_date":" 11/28/2022","study_txt":" Completion: 11/28/2022","study_completion_date":" 11/28/2022","last_update_posted":"2023-09-15"}]